Celgene is expected to report earnings of $1.96 per share on $3.50 billion in revenue. Meanwhile, the so-called Whisper number is $1.99.
Teva is expected to report earnings of $0.66 per share on $4.80 billion in revenue. Meanwhile, the so-called Whisper number is $0.70.
Gilead Sciences will pay up to $90 million over three years to Verily to run a suite of tests on the white blood cells of patients with rheumatoid arthritis, inflammatory bowel disease, and lupus in the hopes of identifying which patients respond to existing drugs.
After developing one of the first therapies to genetically engineer white blood cells to attack cancer, and then selling their company, Kite Pharma, to Gilead for $11.9 billion, what do Arie Belldegrun and David Chang do next?